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A B S T R A C T
The lymphocyte cytokinesis-block micronucleus (CBMN) assay has been applied in hundreds of in vivo
biomonitoring studies of humans exposed to genotoxic chemicals because it allows the measurement of
both structural and numerical chromosome aberrations. The CBMN cytome assay version which, apart
from measuring micronuclei (MN) already present in cells in vivo or expressed ex vivo, also includes
measurement of nucleoplasmic bridges (NPB), nuclear buds (NBUD), necrosis and apoptosis, is also
increasingly being used in such studies. Because of the numerous published studies there is now a need
to re-evaluate the use of MN and other biomarkers within the lymphocyte CBMN cytome assay as
quantitative indicators of exposure to chemical genotoxins and the genetic hazard this may cause. This
review has identiﬁed some important misconceptions as well as knowledge gaps that need to be
addressed to make further progress in the proper application of this promising technique and enable its
full potential to be realised. The HUMN project consortium recommends a three pronged approach to
further improve the knowledge base and application of the lymphocyte CBMN cytome assay to measure
DNA damage in humans exposed to chemical genotoxins: (i) a series of systematic reviews, one for each
class of chemical genotoxins, of studies which have investigated the association of in vivo exposure in
humans with MN, NPB and NBUD induction in lymphocytes; (ii) a comprehensive analysis of the
literature to obtain new insights on the potential mechanisms by which different classes of chemicals
may induce MN, NPB and NBUD in vitro and in vivo and (iii) investigation of the potential advantages of
using the lymphocyte CBMN cytome assay in conjunction with other promising complementary DNA
damage diagnostics to obtain an even more complete assessment of the DNA damage proﬁle induced by
in vivo exposure to chemical genotoxins in humans.
  2014  The  Authors. Published by Elsevier  B.V.    
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The cytokinesis-block micronucleus (CBMN) assay in human
lymphocytes has become one of the most widely used methods for§ This is an open-access article distributed under the terms of the Creative
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Open access under CC BY-NC-ND licenmeasuring structural and numerical chromosomal changes in
human cells in vitro and in vivo [1–4]. Micronuclei (MN) result from
acentric chromosome fragments or whole chromosomes lagging
behind during metaphase/anaphase transition, and require cell
division in vivo or in vitro to be expressed [1–3]. The use of the
CBMN assay in in vitro genetic toxicology testing is well established
and in fact it has become an accepted standard method to assess
the genotoxic hazard of chemicals which led to the development of
an OECD (Organisation for Economic Cooperation and Develop-
ment) guideline for this purpose [2]. For in vitro testing cultures of
unsynchronised mitogen-stimulated lymphocytes are treated inse.
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Fig. 1. The known mechanisms by which genotoxic chemicals may induce
micronuclei and nucleoplasmic bridges in cytokinesis-blocked lymphocytes.
Cenve, centromere negative; Cen+ve, centromere positive; NBUD, nuclear
buds; NPB, nucleoplasmic bridges; MN, micronuclei; ROS, reactive oxygen
species; RNS, reactive nitrogen species. The question mark (?) indicates
insufﬁcient knowledge about the mechanism and/or some uncertainty about the
connection between the two related events.
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following mitosis to measure micronuclei in once-divided cells, thus
maximising the efﬁciency of detecting aneugens or clastogens acting
at different stages of the cell cycle [1–3]. Parallel micronucleus
scoring in non-divided cells, reﬂecting slower cycling cells and/or
mitotic slippage, is also recommended in particular if an aneugenic
mode of action is suspected [2,3]. The CBMN assay is also widely
used in human biomonitoring of in vivo exposure to genotoxins and
has become a standard biodosimetry method endorsed by the
International Atomic Energy Agency and the World Health
Organization for measuring exposure to ionising radiation [4].
The assay measures micronuclei (MN) and other nuclear anomalies
in ex vivo mitogen stimulated lymphocytes from in vivo exposed
persons, integrating in this way in vivo systemic exposure of
lymphocytes and in vivo/ex vivo response to the genotoxic stress. Its
predictivity for the detection of genetic risks is supported by the fact
that it allows measurement at the single cell level of both structural
and numerical chromosome aberrations [1,3]. Moreover, its
predictivity for cancer was demonstrated in humans [5]. However,
the use of the CBMN assay for detecting in vivo exposure to genotoxic
chemicals is somewhat controversial because of the extremely wide
diversity of chemicals, the multitude of direct or indirect mecha-
nisms of their interaction with the genome, the wide spectrum of
DNA lesions they may induce and the variety of cellular death/
survival responses they may trigger. Comprehensive reviews about
the mechanistic, methodological and epidemiological aspects of the
use of micronucleus assays were recently published [1–7], but
systematic reviews on the application of the lymphocyte CBMN
assay for in vivo biomonitoring of chemical exposure are limited to
only a few categories of chemicals such as pesticides [8].
2. Key questions regarding the use of the lymphocyte CBMN
assay for in vivo biomonitoring of human exposure to genotoxic
chemicals
Despite the extensive evidence available in the literature, a
number of key aspects remain unresolved about the origin of MN in
the lymphocyte CBMN assay following in vivo genotoxic chemical
exposure and the signiﬁcance of MN as indicators of chemical
carcinogenesis. These issues raise important questions that
deserve further investigation:
1. What are the direct or indirect mechanisms by which different
classes of genotoxic chemicals induce structural and/or numer-
ical chromosome aberrations and which of these lead to MN
formation?
2. Is the CBMN assay as conventionally used in human biomoni-
toring able (or sensitive enough) to detect exposure to all classes
of chemical genotoxins?
3. Which classes of chemical genotoxins can be detected and
which ones cannot be detected by the lymphocyte CBMN assay?
4. Can the conventional lymphocyte CBMN assay also be used to
measure in vivo induced MN that are already present in the cells?
5. Can the CBMN assay protocol be modiﬁed to improve the
sensitivity to DNA lesions that are not efﬁciently converted to
micronuclei?
6. Does the inclusion of other nuclear anomalies such as
nucleoplasmic bridges and nuclear buds in the ‘‘cytome’’
version of the method improve the sensitivity of the CBMN
assay for detecting in vivo chemical genotoxin exposure?
7. Which other complementary DNA damage biomarkers should
be used in combination with the CBMN cytome assay to enhance
the detection of DNA damage induced by chemical genotoxins?
Considerations and some answers related to these questions are
addressed below.2.1. What are the direct or indirect mechanisms by which different
classes of genotoxic chemicals induce structural and/or numerical
chromosome aberrations and which of these lead to MN formation?
Direct mechanisms by which chemical genotoxins can cause
structural chromosome aberrations or numerical chromosome
changes mainly include the formation of small or bulky adducts,
DNA strand cross-links, DNA-protein cross-links and DNA strand
breaks [9,10]. Indirect mechanisms include inhibition of DNA
repair, impairment of chromosome segregation, disruption of
mitotic checkpoints machinery, inhibition of apoptosis, perturba-
tion of cytokinesis, inhibition of enzymes involved in the
maintenance of DNA methylation, and induction of inﬂammation
and/or mitochondrial dysfunction leading to increased oxidative
stress [3,11].
MN arise mainly from either acentric chromosome fragments or
whole chromosomes. Acentric chromosome fragments originate
from unrepaired DNA strand breaks or misrepair of DNA strand
breaks leading to the formation of an acentric chromosome
fragment which often occurs in conjunction with formation of a
dicentric chromosome [3,4,11]. MN may also arise when a
dicentric chromosome breaks in more than one site when
stretched to the opposite poles of a cell during anaphase [3,11].
Malsegregation of whole chromosomes may be induced if the
chemical either causes centromere or kinetochore malfunction or
disrupts the mitotic spindle or centrosome [3,6,11]. The direct
mechanism of DNA damage induction has been demonstrated for
only a limited number of genotoxic chemicals while for most of the
thousands of man-made or natural chemicals neither the direct or
indirect mechanism of DNA damage induction has been estab-
lished [9,10]. Furthermore interactive effects with endogenous
genotoxins in the body ﬂuid exposome (e.g. reactive oxygen or
nitrogen species, acetaldehyde, high free iron concentration etc.) is
virtually unexplored.
The known mechanisms of how chemicals may induce MN
formation are presented schematically in Fig. 1, although there are
likely to be several others that we are not yet aware of. The various
types of chromatid and chromosome aberrations that contribute to
MN and NPB formation are illustrated in Fig. 2.
Fig. 2. The principal chromatid and chromosome aberrations that contribute to MN and nucleoplasmic bridge formation in the CBMN cytome assay.
Adapted from Savage JRK (2000) Micronuclei: pitfalls and problems. Atlas Genet Cytogenet Oncol Haematol (http://atlasgeneticsoncology.org/Deep/MicronucleiID20016.
html).
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biomonitoring able (or sensitive enough) to detect exposure to
chemical genotoxins?
The conventional use of the CBMN assay in human biomonitor-
ing of chemical genotoxin exposure involves the collection of a
blood sample following acute or chronic in vivo exposure to the
suspected chemical agent or complex mixture. The lymphocytes in
the blood sample are then stimulated to divide ex vivo using a
mitogen, and MN scored in cells that have divided once which are
recognised by their binucleated appearance after cytokinesis-block
(using cytochalasin-B) of the cells from the ﬁrst mitotic cycle
[1–3,6]. The bulk of peripheral blood lymphocytes are long-lived T
cells and it is these cells that are mainly stimulated to divide by the
mitogen used in most studies (i.e. phytohaemagglutinin). A
proportion of these lymphocytes may already contain MN induced
in vivo and many of them may have accumulated various types of
DNA damage depending on the ‘‘exposome’’, i.e. the exposure to
the wide range of genotoxins in body ﬂuids resulting from cellular
metabolism including inﬂammation, and/or from environmental
genotoxins absorbed into the body that may be either metaboli-
cally activated or detoxiﬁed [12,13]. Therefore, it is ultimately the
entire exposome resulting from systemic exposure that deter-
mines the proﬁle of genotoxic insult that the lymphocytesexperienced before being stimulated to divide ex vivo to express
MN in the CBMN assay. It is the nature of the in vivo exposome in
combination with the individual’s genetic and epigenetic back-
ground that ultimately determines the expression of MN ex vivo
after one nuclear division.
Speciﬁc in vitro experiments with the CBMN assay in which
lymphocytes were exposed only in G0 phase (i.e. prior to mitogen
stimulation) show that the MN index in the CBMN assay can
efﬁciently detect exposure to agents that predominantly induce
DNA strand breaks because these lead to acentric chromosome
fragments within one cell cycle if they are left unrepaired or if they
are mis-repaired [3,14]. Repair of double DNA strand breaks can
occur during G0, G1 and G2 with either the error prone non-
homologous end-joining (NHEJ) or the error free homologous
recombinational repair (HRR) mechanism [15] while repair of
single strand breaks occurs via a global pathway involving PARP1
as the sensor and XRCC1 as the molecular scaffold protein [16].
Genetic defects in either of these pathways can lead to acentric
fragment and dicentric chromosome formation. Acentric chromo-
some fragments lead to MN formation because the fragments
cannot engage with the spindle and thus are not included in the
main nuclei during anaphase/telophase.
Some chemicals may predominantly, but not necessarily
exclusively, induce either small or bulky DNA adducts. The
M. Kirsch-Volders et al. / Mutation Research 759 (2014) 49–5852presence of DNA adducts normally triggers the excision repair
pathways that lead to the excision of the damaged base or
template, producing temporary abasic sites, gap-ﬁlling by DNA
polymerase and ligation of the newly synthesised DNA strand to
the adjacent DNA [17]. Failure of any of these processes can lead to
the accumulation of residual unrepaired DNA adducts, abasic sites
and single-stranded DNA breaks. These DNA lesions may, to
varying extents, depending on the adduct and the repair capacity of
the cells, lead to replication stress during S-phase and the
formation of single or double-stranded DNA breaks [18,19].
Chemicals that predominantly induce DNA adducts that cause
stalling of DNA replication forks appear to induce mainly
chromatid-type aberrations such as chromatid breaks, chromatid
gaps and chromatid rearrangements involving only one chromatid
of the chromosome pair at metaphase [20–22] (Fig. 2). The
efﬁciency with which these chromatid-type aberrations are
converted to MN or other nuclear aberrations is unknown.
The limited evidence available appears to suggest that some
chemicals (e.g. methylnitrosourea) or physical agents (ultraviolet
radiation) that mainly induce DNA base adducts or lesions may
not efﬁciently induce MN if lymphocytes are exposed in the G0
phase only [23]. This relative insensitivity may be overcome by
using a modiﬁed CBMN assay protocol in which cells are treated
with cytosine arabinoside (ARA-C) during G1 prior to S-phase to
inhibit the gap-ﬁlling step during base excision repair and thus
converting base excision-repair sites into abasic sites which leads
to single or double strand break formation (if the excision sites are
in close proximity across strands) in G1 phase [23,24] and
ultimately converted to chromatid aberrations that can be
expressed as MN.
The lymphocyte CBMN assay is also sensitive in vitro and ex vivo
to DNA inter-strand cross-linking agents such as acetaldehyde and
mitomycin-C as well as DNA-protein cross-linking agents such as
formaldehyde [25–30]. The Fanconi anaemia/BRCA pathway is
mainly involved in the repair of these important DNA lesions
[31,32]. Acetaldehyde and formaldehyde are generated during
normal metabolism and are also amongst the most ubiquitous
man-made environmental genotoxins/carcinogens [25,28,30,31].
The precise mechanisms by which these agents cause MN is not
known in detail but they could cause chromosome- and chroma-
tid-type aberrations in lymphocytes possibly due to indirect
induction of DNA strand breaks as a result of incomplete DNA
repair of the cross-links and the consequent replication stress
events from stalling replication forks [18–32].
Other classes of chemicals that can result in MN formation are
those affecting the structure of critical regions of the chromosomes
(e.g. centromeres, kinetochores, cohesins, telosome proteins) and
the mitotic or cytokinetic checkpoints machinery (e.g. centro-
somes, microtubules) required for accurate segregation of
chromosomes during mitosis. Some chemical agents may affect
chromosomal instability indirectly. For example, occupational
exposure to nitrous oxide (an anaesthetic gas used routinely in
hospitals), causes inhibition of methionine synthase by oxidising
and inactivating its cofactor vitamin B12 leading to a reduction in
methylation capacity of cells and induction of MN in vivo [33,34].
Hypomethylation of centromeric DNA leads to despiralisation of
the centromere and its dysfunction leading to chromosome
malsegregation and MN formation [35,36]. Some of the most
potent MN inducers are DNA methyltransferase inhibitors such as
5-azacytidine and mutations in DNA methyltransferase genes
[37,38].
The mitotic process involves a complex choreography of
multiple proteins and checkpoints and it is, therefore, not
improbable that environmental chemicals which can adduct to
mitotic proteins may also have signiﬁcant impacts on this process
in vivo. Given that a large proportion of spontaneous MN arecentromere positive it is reasonable to be concerned about our lack
of knowledge of the environmental causes and consequences of
this important genetic pathology. Although adducts to proteins in
the mitotic machinery may indicate risk of mitotic defects,
chromosome malsegregation is currently best analysed directly
by the CBMN assay in combination with centromere speciﬁc
probes to identify MN originating from whole chromosomes or
abnormal chromosome distribution amongst nuclei in a binucle-
ated cell [6,11]. Whether the in vivo exposure to such agents causes
MN formation ex vivo in the CBMN assay was almost never
assessed and can only be expected to detect these exposures if the
in vivo exposure causes long lasting damages to the relevant
chromosome and mitotic machinery targets (e.g. centromeres and
kinetochores, respectively) [3,11].
2.3. Which classes of chemical genotoxins can or cannot be detected
by the lymphocyte CBMN assay as used for human bio-monitoring?
In principle, the CBMN assay can only detect genotoxin
exposure when used in human bio-monitoring if (i) micronuclei
are induced in vivo and are not eliminated by apoptosis or (ii) if the
DNA damage in the G0 lymphocytes is not repaired and can be
converted to MN ex vivo during their ﬁrst mitotic division or (iii) if
the in vivo exposure causes long lasting damages to the relevant
chromosome and mitotic machinery targets. There is in vitro
evidence that some chemicals which predominantly induce DNA
adducts (e.g. methylnitrosourea) may not be able to induce MN if
lymphocytes are exposed in G0 only, however, it is not yet clear
whether this applies to all chemicals that predominantly induce
DNA adducts or all types of adducts (e.g. small versus bulky
adducts). Furthermore, it is improbable that a chemical will only
induce DNA adducts and not affect other cellular structures and
DNA maintenance pathways which, if impaired, may also induce
MN formation. There is clearly a need to determine which of the
chemicals that predominantly induce DNA adducts will not induce
MN in the conventional CBMN assay protocol for bio-monitoring if
exposure occurs only in G0.
2.4. Can the conventional lymphocyte CBMN assay also be used to
measure in vivo induced MN that are already in the cells?
MN were ﬁrst described in human erythrocytes more than 100
years ago and later shown to be due to chromosome aberrations in
normoblasts in the bone marrow caused by folate and/or vitamin
B12 deﬁciency [1,39–42]. It is known that MN can also be induced
in lymphoblasts in the bone marrow and lymph nodes during
lymphocyte proliferation [1,41–43]. Therefore a genotoxic expo-
some in the body is expected to induce MN in vivo in lymphocytes.
In a paper on the effects of chronic exposure to radiation we
showed that MN in non-divided lymphocytes in the CBMN assay
were also a good indicator of exposure when compared to MN in
cytokinesis-blocked binucleated cells [44]. We, in fact, proposed
that MN should also be scored in non-divided mononucleated cells
within the CBMN assay and that the most efﬁcient time to do this
could be 24 h after PHA stimulation when the cytoplasm is
enlarged making it easier to observe the MN in cells [6,44,45].
Whether scoring MN in non-divided cells is best done at 0, 24 h or
at 72 h when the CBMN assay culture is typically harvested has not
yet been tested. Perhaps mononucleated cells with MN may
undergo apoptosis as they progress through the cell cycle ex vivo or
may reappear if they complete nuclear division [45]. Live cell
imaging studies suggest that cells with MN tend to either not
proliferate or terminate apoptotically but those that do divide tend
to generate daughter cells with MN [46]; whether this also applies
to human lymphocytes in vivo or ex vivo has not yet been
determined.
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to chemically induced DNA lesions that are not repaired or efﬁciently
converted to micronuclei?
There are essentially three ways that the CBMN assay protocol
has been modiﬁed or is being modiﬁed to capture DNA lesions that
are not efﬁciently converted to micronuclei:
(i) As indicated above it is possible to convert excision repairable
DNA lesions to DNA strand breaks within one cell cycle by
treating with ARA-C (an inhibitor of the gap ﬁlling step of base
excision repair) during G1 phase post PHA stimulation ex vivo
in culture We have shown that this approach increases the
sensitivity to DNA damage from ionising radiation 1.8-fold, UV
40-fold and in the case of MNU from undetectable to a steep
dose-response curve. The mechanism was veriﬁed because, as
predicted, the majority of ARA-C induced MN were due to
acentric chromosome fragments [23,24]. However, it is not yet
clear whether unrepaired DNA adducts induced in vivo can
also be efﬁciently converted to DNA strand breaks and MN ex
vivo using the ARA-C protocol.
(ii) DNA probes and/or antibodies can be used in the CBMN assay
to measure mal-segregation of chromosomes between nuclei
of binucleated cells, telomere and centromere content of
nuclei and micronuclei, as well as a variety of DNA damage
response proteins and DNA adducts all of which can provide
additional information on chemically induced genomic insults
[3,6,11].
(iii) Because many genotoxic chemicals also induce necrosis,
apoptosis and cytostasis to varying degrees it is also important
to score these events to obtain a complete picture of the
toxicity proﬁle and also capture any cells with DNA damage
that have become apoptotic [3,6]. These cell types and the ratio
of mononucleated, binucleated and multinucleated cells to
measure the nuclear division index are included in the cytomeFig. 3. The stages in the lymphocyte CBMN cytome assay when MN and other nuclear ano
mononucleated cells prior to completion of mitosis and after mitosis in binucleated cell
respectively. CYT-B, cytochalasin-B; MN, micronuclei; NBUD, nuclear buds; NPB, nucleversion of the CBMN assay. The extent to which these
biomarkers correlate with DNA adduct load and other DNA
damage events is not clear because it has not been
methodically investigated.
2.6. Does the inclusion of other nuclear anomalies such as
nucleoplasmic bridges and nuclear buds in the ‘‘cytome’’ version of the
method improve the sensitivity of the CBMN assay for detecting in vivo
chemical genotoxin exposure?
The CBMN cytome assay (Fig. 3) also includes additional
biomarkers of chromosomal instability such as nucleoplasmic
bridges (NPBs) and nuclear buds (NBUDs). NPBs may arise from
dicentric chromosomes or chromatids caused by mis-repair of DNA
breaks or due to telomere end fusions caused by telomere
dysfunction; in addition NPBs may also be caused by incomplete
separation of chromatids during the metaphase to anaphase
transition [3,47]. NBUDs originate from nuclear removal of
unresolved DNA repair complexes and excess ampliﬁed DNA;
they may also be induced by breakage of NPBs [3]. NPBs and NBUDs
have widened the spectrum of DNA damage events detectable by
the CBMN assay but the classes of chemicals that efﬁciently induce
these biomarkers are yet to be deﬁned. The use of NPBs in the
CBMN cytome assay is unique amongst biomarkers of genotoxicity
because it is the only method that can measure defects in
chromatid separation during anaphase which leads to chromo-
somal instability [3,6]. The growing number of studies using the
comprehensive CBMN cytome assay will make it possible to
identify the relative sensitivities of MN, NPB and NBUD to different
classes of chemical genotoxins and their proﬁle uniqueness with
respect to chemical type. For example it was shown that the NPB/
MN ratio was much higher in WIL2-NS cells after activated
neutrophil exposure than it was for superoxide or hydrogen
peroxide [48]. A study of workers exposed to vanadium pentoxide
showed that NPBs were increased to a much greater extent thanmalies can be measured in cells exposed in vivo to genotoxicants. Measurements in
s allows discrimination between MN expressed in vivo and those expressed ex vivo
oplasmic bridges; PHA, phytohaemagglutinin.
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lymphocytes of smokers were associated with lung cancer to a
much greater extent as compared to MN [50,51].
2.7. Which other complementary genome/chromatin damage
biomarkers should be used in combination with the CBMN cytome
assay to enhance detection of chemical genotoxin exposure?
The CBMN cytome assay, being a multiple biomarker system,
can capture many types of damages induced by the myriad of
genotoxic chemicals and their combinations. Nevertheless, it is
advisable to consider using a high content analysis (HCA) approach
in the application of the CBMN cytome assay by combining it with
molecular detection systems to also measure presence or absence
of centromere/s or telomere/s within MN, NPB or NBUD, as well as
DNA damage response proteins (e.g. gH2AX as a biomarker of DNA
strand breaks), DNA adducts (e.g. 8-OHdG as a biomarker of
oxidative DNA damage), DNA methylation and telomere content
within the nuclei. In addition it has recently been shown that gene
expression proﬁling could also be used to identify the metabolic
and DNA maintenance pathways associated with the CBMN assay
biomarkers which can then provide a clue of which aspect of the
exposome was the likely causative factor [52,53]. Therefore, there
is a need to reconsider whether a HCA CBMN cytome assay that
may or may not include an ARA-C step will provide a better
assessment of chemical genotoxin exposure and its genetic
consequences.
3. Misconceptions and knowledge gaps about the sensitivity of
the CBMN assay for detecting exposure to chemical genotoxins
The questions and considerations described above should not
be confused with misconceptions that have emerged recently
about the use and reliability of the lymphocyte CBMN assay for
measuring DNA damage caused by in vivo exposure to chemical
genotoxins [54]. Uncertainties about the reliability of results
obtained with the lymphocyte CBMN assay to measure in vivo DNA
damage induced by chemicals may be due to (i) a paucity of
systematic critical reviews of the vast literature and data on the use
of CBMN assay in population bio-monitoring of genotoxic chemical
exposure and/or (ii) limited knowledge of the varied and multiple
mechanisms by which a genotoxic chemical may directly or
indirectly cause damage to DNA and the mitotic apparatus that can
lead to MN formation and other associated nuclear anomalies in
lymphocytes in vivo. It has therefore become necessary to discuss
the apparent knowledge gaps associated with these misconcep-
tions that have emerged recently in the literature:
3.1. Misconception #1: the CBMN assay excludes MN being scored in
non-divided cells
The CBMN assay as originally conceived has, since 15 years ago,
evolved into a CBMN cytome assay that apart from scoring MN in
binucleated cells also includes scoring MN in non-divided
mononucleated cells as well as apoptotic cells to take account of
their possible elimination by programmed cell death. This was ﬁrst
recommended by Fenech et al. [44] and subsequently by Kirsch-
Volders and Fenech [45]. By using this protocol MN that are already
expressed in vivo are also captured in the assay. There are now
several published studies that use this approach [44,55–58]. For
example, Fucic et al. [55] showed that the MN frequency in
binucleated lymphocytes ex vivo in newborns was signiﬁcantly
lower than in their mothers but higher in mononuclear lympho-
cytes suggesting a higher susceptibility for MN induction in vivo
but a lower propensity for MN expression ex vivo in newborns
relative to their mothers. The reasons for such differences are notknown but the results suggest the possibility of increased
sensitivity of the newborn to MN induction in vivo induced by
metabolic/oxidative stress during the late stages of pregnancy
particularly if the mother has an elevated body mass index [55,56].
This example and the others mentioned above highlight the
opportunity of a more comprehensive assessment of the origins of
DNA damage by scoring MN that are already present in
lymphocytes and those expressed ex vivo in once-divided
binucleated cells.
3.2. Misconception #2: MN produced in vivo do not substantially
contribute to MN frequency measured in binucleated lymphocytes in
the ex vivo CBMN assay
The only reliable way to know whether MN produced in vivo
contribute to MN formation in binucleated cells in the ex vivo
CBMN assay is to follow, by live-cell imaging, the fate of
lymphocytes that already contain MN prior to mitogen stimula-
tion. No such studies have yet been performed in lymphocytes.
Even if these cells did not survive and became apoptotic they
would still be detected as apoptotic cells in the CBMN cytome
assay [6]. Furthermore, if they are delayed in undergoing mitosis
they would be detected as MN in mononucleated cells anyway
[44,45].
3.3. Misconception #3: the sensitivity of the CBMN assay for detection
of MN in binucleated cells is diminished because cytochalasin-B is
added late during the culture period so that the binucleated cells
scored do not always represent cells that have completed one cell cycle
only
In the CBMN lymphocyte assay cytochalasin-B (CYT-B) is added
44 h after mitogen stimulation to block cytokinesis, so that cells
that have completed one nuclear division can be easily identiﬁed
by their binucleate appearance and then scored for MN and other
nuclear anomalies. There is as yet no evidence to suggest that
adding CYT-B earlier than 44 h improves the sensitivity of the
CBMN assay. A protocol based on adding CYT-B at 24 h post PHA
stimulation and harvesting at 48 h showed that only 5% of cells
were accumulated as binucleated cells during this period [59]
which is a very small fraction compared to binucleated cell
frequencies of between 30% and 50% for protocols based on adding
CYT-B at 44 h and harvesting at 72 h. Furthermore, cells with DNA
damage may experience cell cycle checkpoint delay, therefore they
are more likely to undergo mitosis at a later rather than an earlier
time-point. At best only 5% of binucleated cells would have
undergone more than one division and there is no evidence to
suggest that this would substantially alter the MN frequency in
binucleated cells.
3.4. Misconception #4: the delay in adding CYT-B means that
damaged cells can be eliminated by apoptosis and/or DNA damage
induced in vivo can be repaired prior to the production of a MN in the
presence of CYT-B. This may render the CBMN assay to be insensitive
As indicated above the CBMN cytome assay includes scoring of
apoptotic cells, therefore DNA damaged cells are not excluded from
the CBMN cytome assay score. The ratio of apoptotic cells to cells
that divide and express DNA damage can be a useful indicator of an
individual’s capacity to trigger apoptosis and therefore may
indicate cancer susceptibility. DNA repair is upregulated when
lymphocytes enter G1 phase [23,24]. By allowing repair to occur
prior to accumulation of binucleated cells the CBMN assay
provides a better indication of the actual genotoxic risk to the
cells in vivo because it takes into account the capacity of the cell to
repair the DNA lesions induced by the exposome which they
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repair or defects in repair which could induce chromosome
aberrations that lead to MN formation [14–16]. This integrated
‘‘genotoxic risk’’ measurement would differ from that of a CBMN
assay where inhibition of DNA repair during the ex vivo step would
be experimentally induced to increase conversion of excision-
repairable DNA adduct lesions to MN and thus reﬂect more closely
‘‘exposure level’’ [23,24]. Both can be interesting but the choice of
the protocol design should also consider this important hazard
versus risk perspective.
3.5. Misconception #5: a comparison with the in vitro CBMN assay
used for genotoxicity testing leads to the conclusion that it is unlikely
that DNA damage induced in vivo is the cause of increased MN
frequencies in binucleated cells after occupational or environmental
exposure to genotoxic chemicals
The in vitro CBMN lymphocyte assay performed according to
the OECD guideline [2] can test the effects of genotoxic chemical
exposure at all stages of the cell cycle as occurs in in vivo exposure
in those tissues of the body where lymphocytes are generated as a
result of cell division and maturation of precursor cells (e.g. bone
marrow and spleen). However, results from in vitro assays may not
accurately predict in vivo effects because in vitro treatment with
chemicals does not replicate all of the complexities of in vivo
exposure such as absorption, metabolic activation or detoxiﬁcation
and excretion of the chemical by other tissues in the body. The
lymphocytes in blood may already contain MN induced in vivo in
the dividing lymphocyte populations and these are captured in
non-divided mononucleated cells that are scored in the CBMN
cytome assay. Furthermore, because a large proportion of
lymphocytes are long-lived they also accumulate DNA damages
(e.g. DNA adducts, DNA strand breaks) depending on the in vivo
exposome and these damages can also lead to the induction of MN,
ex vivo after one cell division in culture, which are scored in the
cytokinesis-blocked binucleated cells in the CBMN assay. The
exposome in an in vitro system consists simply of the composition
of the culture medium, the test chemical and any solvent used;
however effects could vary depending on the nutritional composi-
tion of the medium which supplies cofactors for DNA replication
and repair and may vary from in vivo effects because the nutritional
composition of typically used culture media varies substantially
from the nutritional proﬁle of body ﬂuids such as plasma [60].
Similarly the genotoxic effects of a chemical in vivo may vary
depending on the nutritional and metabolic status of the subjects
investigated and could be further complicated by other concurrent
genotoxin exposures that may interact with the chemical exposure
being investigated [3,56,60]. Therefore, in vivo exposure to a
chemical genotoxin will, ultimately, contribute to the totality of
the genotoxic in vivo exposome which induces the various other
DNA lesions already present that can also lead to MN formation in
lymphocytes in vivo and/or ex vivo.
A PubMed search for biomonitoring studies investigating
lymphocyte MN frequency in populations exposed to chemical
genotoxins yields hundreds of publications, the majority of which
indicating signiﬁcant increases in MN frequency in cohorts
exposed to a wide range of genotoxic chemicals (e.g. pesticides,
benzene, formaldehyde, vinyl chloride, polycyclic aromatic hydro-
carbons, heavy metals cytotoxic drugs). For example, since 1993,
seventeen in vivo studies of formaldehyde exposure in humans, in
different settings, were published [27,61–76]. All of these studies,
except two, reported signiﬁcant increases in the frequency of MN
in the lymphocyte CBMN assay for the exposed groups relative to
the controls. Furthermore four of ﬁve studies showing an increase
in oral and/or nasal MN frequency in those exposed to formalde-
hyde also showed a signiﬁcant increase in MN frequency in thelymphocyte CBMN assay in these groups relative to controls
[61,62,67,68,73]. These data clearly support the notion that the
CBMN assay is sensitive to in vivo exposure from genotoxic
chemicals such as formaldehyde. Furthermore, it is well docu-
mented that mutagens which induce MN in lymphocytes in the
CBMN assay are also likely to initiate cancer [2,5,7,50–53]. In
addition, proof for the assumption that MN reﬂect DNA damage in
humans comes from positive ﬁndings in several MN studies with
lymphocytes which were performed with population groups with
occupational and lifestyle related exposures to known genotoxins
and/or with certain DNA maintenance pathologies (e.g. DNA repair
and DNA methylation deﬁciencies) that are known to be associated
with increased cancer rates [5,8,14,25–42,48–52]. In this context it
is also notable that the epidemiological evaluation of data from
6718 subjects from 10 countries indicates that MN rates in
lymphocytes are a predictive biomarker for human cancer risks
[77].
However, a systematic assessment of all published peer-
reviewed studies, for each class of chemicals, is required to
determine effect sizes, statistical signiﬁcance and consistency
across investigations depending on the quality of study designs. At
this stage, the available published data has not been properly
analysed to determine (i) whether the CBMN cytome assay, as
currently performed, can detect all types of chemical genotoxin
exposures and their associated genetic hazard or (ii) the exposure
levels that may be below the detection limit of the assay. Increases
in MN frequency in the lymphocyte CBMN assay reported in a
multitude of chemical occupational exposure studies in the peer-
reviewed literature are more likely to be accepted by experts in the
ﬁeld when the mechanisms by which chemicals might induce MN
in lymphocytes in vivo or ex vivo are properly elucidated and
proven. It is also reasonable to consider whether studies reporting
positive results were properly controlled for other factors such as
diet, life-style, gender and age which may also contribute to the
MN frequency index [7]. Finally the high positive correlation
(R2 = 0.74) of MN induction by chemical genotoxins in the
occupational setting observed between lymphocytes in the CBMN
assay and buccal cells [78] adds support to the evidence that MN
scored in lymphocytes in the ex vivo CBMN assay do in fact
represent DNA damage induced in vivo because MN in buccal cells
are expressed entirely and solely in vivo.
4. Is it possible to further improve the CBMN cytome assay for
detecting exposure to genotoxic chemicals and to measure the
genetic hazard/risk associated with such exposures?
Because MN and associated nuclear anomalies can be induced
by different exposures such as nutritional deﬁciency, ionising
radiation and direct- or indirect-acting chemical genotoxins it is
not possible to be absolutely certain how they may have been
induced. However it is possible to use the CBMN cytome biomarker
proﬁle to determine the mechanism by which they were induced.
For example exposure to ionising radiation typically increases the
frequency of MN and NPB and the majority of induced MN are
centromere negative [3,4,14]. In contrast chemicals which induce
chromosome malsegregation result in the formation of MN that are
centromere positive and the daughter nuclei have abnormal
numbers of chromosomes (even in the absence of MN induction)
which can be detected using chromosome speciﬁc centromere
probes. Another approach is to use molecular probes to detect
speciﬁc DNA adducts (e.g. antibodies to 8-oxoguanine, or polycy-
clic aromatic hydrocarbon adducts) within the nuclei or DNA
damage response proteins that are speciﬁc to the mechanism of
action of the genotoxin. For example, phosphorylated gH2AX can
be used to measure the formation of double stranded DNA breaks
within the nuclei of cells scored although this biomarker is also
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as obesity [79]. In a recent study with heavy ions it was possible to
show that micronuclei resulting from such an exposure speciﬁcally
express gH2AX and SMAD7 [80]. It is possible that a selection of
DNA damage response proteins expressed in MN and the nucleus
of the cell they inhabit could shed more light on exposure to
speciﬁc genotoxins. Another important aspect to consider is also
the possibility of detection of chromosome shattering (chromo-
thripsis) occurring within MN due to incomplete DNA replication
and ligation of Okazaki fragments during the mitotic cycle. The
induction of this defect is considered a key mechanism in the
formation of highly rearranged chromosomes (chromoanagenesis)
typically observed in cancers [81,82].
Given the relative non-speciﬁcity of MN induction with respect
to genotoxin exposure it is reasonable to expect that the CBMN
cytome assay on its own may not provide sufﬁcient information on
the full extent of genotoxin exposure. On the other hand, the
sensitivity of the assay to diverse genotoxins acting through
various mechanisms, together with its capacity to also measure
NPBs, NBUDs, necrosis, apoptosis and cytostasis in cytome mode,
makes it one of the more suitable techniques to capture the genetic
and cytotoxic hazard posed by multiple genotoxins and their
interactions within the exposome of a human body as well as the
impact of susceptibility caused by genetic defects and nutritional
deﬁciencies/excesses.
Another aspect to consider is that in the lymphocyte CBMN
cytome assay, apart from measuring MN that are already present
within lymphocytes, it also measures DNA damages accumulated
in the body that are readily converted into MN when dividing ex
vivo in culture [3–6]. Because the ex vivo culture should reﬂect
what might happen in the body if the damaged lymphocytes were
to divide in vivo it may be worthwhile exploring whether culturing
of lymphocytes in medium that uses plasma from the blood of the
individual being tested instead of foetal bovine serum, and has
physiological amounts of micronutrients required for DNA repair
may further enhance sensitivity of the assay. In fact the
micronutrient composition of culture medium is non-physiologi-
cal if compared to the composition of human serum or plasma and
efforts are underway to develop culture media that better
represent the human body ﬂuid conditions [60].
As has been the case with in vitro genotoxicity testing we are at
a stage when it has become important to reconsider what is the
best combination of genotoxicity assays to measure (i) the extent
of exposure to genotoxins within the human body and (ii) the
genetic hazard and disease risk posed by exposomes of varying
complexity.
5. A road map to resolve the knowledge and technological gaps
in the use of the lymphocyte CBMN cytome assay for detection
of chemical genotoxin exposure and the induced genetic
hazard/risk
The HUMN project, originally established in 1997 (www.humn.
org), has over the past 16 years contributed greatly to improving
the application and understanding of lymphocyte and buccal cell
micronucleus assays in human biomonitoring and determining the
health risk associated with elevated MN frequencies. Based on this
experience we propose the following key steps to resolve the
knowledge and technological gaps in the use of the lymphocyte
CBMN cytome assay for the detection of chemical genotoxin
exposure and the induced genetic hazard/risk:
(1) There are hundreds of papers describing studies with the CBMN
and/or CBMN cytome assay of medical, environmental and
occupational exposure to single chemical genotoxins and
complex mixtures. With the exception of exposure topesticides [8] these studies have not been previously system-
atically reviewed. We propose that a systematic review of all of
these studies by experts in the ﬁeld be performed to determine
the quality of study designs, the adequacy of statistical
analyses, and the extent to which the lymphocyte CBMN
cytome assay biomarkers were associated with exposure to
genotoxic agents depending on class of chemical and dose. The
extent to which genotype affects the effect size and the
plausibility of an effect depending on mechanism should also
be assessed when possible. Furthermore, in studies, where
other genotoxicity assays were used, it will be useful to also
provide an estimate of the effect size of the CBMN cytome assay
biomarkers relative to DNA damage measured by other assays.
A series of systematic reviews, one for each class of chemical
genotoxins, of studies which have investigated the association
of in vivo exposure in humans with MN, NPB and NBUD
induction measured using the lymphocyte CBMN cytome assay
is recommended.
(2) It is becoming increasingly evident that a genotoxic chemical
may have multiple targets other than DNA that can directly or
indirectly also cause chromosomal instability and mitotic
malsegregation events that can lead to formation of MN, NPBs
and NBUDs (Fig. 1). Therefore, it is now important to review the
literature to obtain new insights on the mechanisms by which
different classes of chemicals may induce MN, NPB and NBUDs
in vivo.
(3) Finally, it should be useful to conduct a series of workshops to
explore how the lymphocyte CBMN cytome assay may be
further improved to increase sensitivity to chemical genotoxins
and discuss the best combination of genotoxicity assays to
comprehensively assess the genome (DNA) damage risk from
single and/or multiple exposures to chemical genotoxins. For
example a recent review on trafﬁc-associated genotoxicity
biomarkers highlighted the importance of an integrated
approach using validated complementary diagnostics of DNA
damage at the chromosomal and molecular level to provide the
strongest mechanistic evidence that exposure to trafﬁc fumes
is likely to be carcinogenic [83]. Achieving a consensus on the
best approach(es) to measure exposure to chemical genotoxins
and associated genetic hazard using the lymphocyte CBMN
cytome assay in conjunction with other techniques should be a
high priority.
One may also consider whether some of the questions about the
suitability of the lymphocyte CBMN cytome assay for detecting in
vivo exposure to a wide range of chemical genotoxins in humans
may be indirectly explored by controlled acute or chronic exposure
studies in rodents which are not ethically possible in humans. In
fact a lymphocyte CBMN ex vivo assay to detect in vivo exposure to
chemical genotoxins and ionising radiation was developed and
validated for the mouse more than 20 years ago [84,85]. It would be
interesting to test whether this approach, or use of MN assays in
target organs such as the lung [86], is more sensitive than the
conventional erythrocyte MN assay which, unlike lymphocytes
which circulate throughout the body, is entirely dependent on the
chemical genotoxin reaching the bone marrow. Nevertheless,
because of the dearth of available evidence, one cannot assume
that data from controlled lymphocyte CBMN assays in rodents will
reliably predict results in humans following in vivo exposure to
chemical genotoxins.
6. Conclusion
In conclusion, the lymphocyte CBMN cytome assay has a great
potential to serve as a reliable biomarker for genetic damage in
biomonitoring studies of chemical genotoxin exposure, essentially
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combines assessment of both structural and numerical chromo-
some aberrations. The growing interest in this method and the
wealth of data that has been accumulated so far has stimulated the
need to re-evaluate the use of MN and other biomarkers within
the lymphocyte CBMN cytome assay as quantitative indicators of
exposure to chemical genotoxins and the genetic hazard/risk they
may cause. This review has identiﬁed some important misconcep-
tions as well as knowledge and technological gaps that need to be
addressed to make further progress in the proper application of
this promising technique and enable its full potential to be
realised.
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